
From Glamor to Reality: How Tobacco Fuels the Lung Cancer Epidemic
2025-04-01
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central Florida, Pensacola, FL 2. Mayo Clinic, Rochester, MN 3. University of Washington/Fred Hutch Cancer Center, Seattle, WA June 2 2024 Key points:
The current standard of care for the treatment of LS-SCLC is platinum-based chemotherapy with concurrent thoracic radiation therapy (cCRT). However, the prognosis remains poor with the overall survival (OS) of approximately 25 months [1]. The ADRIATIC trial (NCT03703297), was presented at 2024 Annual Meeting of ASCO in Chicago. This randomized phase 3 clinical trial enrolled a total of 730 patients with stage I to III LS-SCLC who completed 4 cycles of concurrent CRT within 1 to 42 days. Patients were randomized in a ratio 1:1:1 to receive durvalumab alone, or in the second intervention arm, durvalumab alongside tremelimumab for up to 4 doses, followed by durvalumab up to 24 months. In the controlled group, patients were administered two intravenous (IV) placebo saline infusions every 4 weeks for the initial 4 cycles, then switched to a single IV placebo saline infusion every 4 weeks for up to 24 months. The primary endpoints are progression-free survival (PFS) and overall survival (OS) between durvalumab group versus placebo group [2]. In this presented study with durvalumab alone data, 264 and 266 patients were enrolled in durvalumab and placebo groups respectively, of both whom 99.6 % received treatment. PFS was significantly prolonged in the durvalumab arm (16.8 months vs. 9.2 months, HR 0.76, 95% CI: 0.61-0.95, P=0.0106). Similarly, OS was statistically better in the durvalumab arm (55.9 months vs. 33.4 months, HR 0.73, 95% CI: 0.57-0.93, P=0.0104). An array of treatment-related adverse events (TRAEs) were reported, the most common of which were decreased appetite (16.8% vs 12.8%), hypothyroidism (16.0% vs 3.8%), cough (15.3% vs 12.1%). In conclusion, consolidation durvalumab will become the new standard of care for patients with LS-SCLC who have completed after cCRT without progression. References
2025-04-01
2025-03-21
Share Article